Literature DB >> 16609907

Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract.

Yasuyoshi Miyata1, Kojiro Ohba, Shigeru Kanda, Koichiro Nomata, Jiro Eguchi, Tomayoshi Hayashi, Hiroshi Kanetake.   

Abstract

The prostaglandin E2 receptor, EP4 receptor (EP4R), plays an important role in the development of transitional cell carcinoma of the upper urinary tract (TCC-UUT). However, the clinical significance of other EP receptors (EP1R-3R) is not clear. Furthermore, the pathological function of EP receptors in such patients is not understood. In the present study, we examined the expression of EP1R-3R in 101 TCC-UUT tissues by immunohistochemistry. Furthermore, we defined the relationship between cyclooxygenase (COX)-2 and EP receptor expression, proliferation index (PI), microvessel density (MVD), and expression of metalloproteinase-2 (MMP-2), urokinase-type plasminogen activator (uPA), and exon v6 containing CD44 isoform (CD44 v6) by multivariate analysis. The expression of EP1R, EP2R, and EP3R was positive in 20 (19.8%), 26 (25.7%), and 14 (13.9%) tumor samples, respectively. Expression of these receptors was not associated with pathological findings or survival. COX-2 and EP4R were independently associated with MVD and MMP-2, and uPA or PI and MMP-2, respectively. Other EP receptors were not influenced by any factors. Our results suggest that EP1R-3R play a minimal role in cancer progression in patients with TCC-UUT. On the other hand, EP4R regulates tumor progression via cancer cell proliferation and MMP-2, distinct from COX-2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16609907     DOI: 10.1007/s00428-006-0198-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  38 in total

1.  Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44.

Authors:  M Dohadwala; J Luo; L Zhu; Y Lin; G J Dougherty; S Sharma; M Huang; M Pold; R K Batra; S M Dubinett
Journal:  J Biol Chem       Date:  2001-04-24       Impact factor: 5.157

2.  Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.

Authors:  Melissa B Hansen-Petrik; Michael F McEntee; Brian Jull; Hang Shi; Michael B Zemel; Jay Whelan
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

3.  Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development.

Authors:  T Kawamori; N Uchiya; S Nakatsugi; K Watanabe; S Ohuchida; H Yamamoto; T Maruyama; K Kondo; T Sugimura; K Wakabayashi
Journal:  Carcinogenesis       Date:  2001-12       Impact factor: 4.944

4.  Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells.

Authors:  Guoping Li; Tian Yang; Jun Yan
Journal:  Biochem Biophys Res Commun       Date:  2002-12-20       Impact factor: 3.575

Review 5.  International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes.

Authors:  R A Coleman; W L Smith; S Narumiya
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

6.  Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

Authors:  Ben S Zweifel; Thomas W Davis; Richard L Ornberg; Jaime L Masferrer
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

7.  Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas.

Authors:  M Kömhoff; Y Guan; H W Shappell; L Davis; G Jack; Y Shyr; M O Koch; S B Shappell; M D Breyer
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

8.  Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.

Authors:  Sung-Hee Chang; Catherine H Liu; Rebecca Conway; David K Han; Kasem Nithipatikom; Ovidiu C Trifan; Timothy F Lane; Timothy Hla
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

9.  Altered eicosanoid levels in human colon cancer.

Authors:  B Rigas; I S Goldman; L Levine
Journal:  J Lab Clin Med       Date:  1993-11

10.  Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells.

Authors:  Y Chen; M Hughes-Fulford
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  8 in total

1.  Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.

Authors:  Laura von der Emde; Diane Goltz; Stefan Latz; Stefan C Müller; Glen Kristiansen; Jörg Ellinger; Isabella Syring
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

2.  PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.

Authors:  Jurairat Jongthawin; Porncheera Chusorn; Anchalee Techasen; Watcharin Loilome; Thidarut Boonmars; Raynoo Thanan; Anucha Puapairoj; Narong Khuntikeo; Wichittra Tassaneeyakul; Puangrat Yongvanit; Nisana Namwat
Journal:  Tumour Biol       Date:  2014-05-18

Review 3.  Macrophages in tumor microenvironments and the progression of tumors.

Authors:  Ning-Bo Hao; Mu-Han Lü; Ya-Han Fan; Ya-Ling Cao; Zhi-Ren Zhang; Shi-Ming Yang
Journal:  Clin Dev Immunol       Date:  2012-06-19

Review 4.  The Fate of the Tumor in the Hands of Microenvironment: Role of TAMs and mTOR Pathway.

Authors:  Danilo Figueiredo Soave; Marina Pacheco Miguel; Fernanda Dias Tomé; Liliana Borges de Menezes; Patrícia Resende Alo Nagib; Mara Rúbia Nunes Celes
Journal:  Mediators Inflamm       Date:  2016-12-15       Impact factor: 4.711

5.  Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.

Authors:  Eiji Kashiwagi; Satoshi Inoue; Taichi Mizushima; Jinbo Chen; Hiroki Ide; Takashi Kawahara; Leonardo O Reis; Alexander S Baras; George J Netto; Hiroshi Miyamoto
Journal:  Br J Cancer       Date:  2017-11-09       Impact factor: 7.640

6.  Gene expression of prostaglandin EP4 receptor in three canine carcinomas.

Authors:  Margaret L Musser; Austin K Viall; Rachel L Phillips; Jesse M Hostetter; Chad M Johannes
Journal:  BMC Vet Res       Date:  2020-06-22       Impact factor: 2.741

Review 7.  Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer.

Authors:  Tomhiro Mastuo; Yasuyoshi Miyata; Tsutomu Yuno; Yuta Mukae; Asato Otsubo; Kensuke Mitsunari; Kojiro Ohba; Hideki Sakai
Journal:  Molecules       Date:  2020-01-29       Impact factor: 4.411

8.  Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model.

Authors:  Masahito Masato; Yasuyoshi Miyata; Hiroki Kurata; Hidenori Ito; Kensuke Mitsunari; Akihiro Asai; Yuichiro Nakamura; Kyohei Araki; Yuta Mukae; Tsuyoshi Matsuda; Junki Harada; Tomohiro Matsuo; Kojiro Ohba; Hideki Sakai
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.